| abstract |
The present invention relates to siRNA molecules for inhibiting the expression of the NRARP gene and methods for their use and their use in pharmaceutical compositions. The invention also relates to the use of the siRNA molecule in the treatment and / or prevention of a disease or disorder associated with neovascularization characterized by increased expression and / or activity of the NRARP gene, wherein the condition of the eye is Age-related macular degeneration (AMD), ischemic retinopathy, diabetic macular edema (DME), proliferative diabetic retinopathy (PDR), diabetic retinal ischemia (DRI), diabetic retinal edema (DRE) and immature It also relates to a use selected from the group comprising retinopathy of prematurity (ROP), as well as combinations thereof. |